Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
Posted on: Monday, 27 August 2007, 09:13 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c66739) has announced the addition of Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology to their offering.
In this triple analysis has analyzed three major and intertwined areas of cancer R&D, Apoptotic agents, Protein Kinase Inhibitors and Anti-Angiogenic agents, which are all subjects to an extensive number of innovative drug candidates.
This extensive 325+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas.
The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Apoptotic Agent Highlights
In-depth competitive landscape assessment of the apoptopic market in oncology. Thorough review of utilized targets in apoptopic drug development. Thorough review of approved drugs. Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls. There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and prostate cancer. A thorough target analysis of drugs in development reveals more than 130 candidate targets for triggering apoptosis in cancer cells.
Protein Kinase Inhibitor Highlights
Drugs according to protein kinase target; Dual or multiple kinase inhibitor analysis targets according to indication competitive landscape assessment. Protein kinase inhibitors on market, thorough review of the seven largest cancer indications in the field of protein kinase inhibitors. The number of protein kinase inhibitor drugs has risen sharply, as the number of targets. The fiercest competition in kinase inhibitor drug development is found in hematological, breast, lung, prostate, and colorectal cancer. Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.
Anti-Angiogenic Agents Highlights
In-depth competitive landscape assessment of the anti-angiogenesis market in oncology. Thorough review of utilized targets in anti-angiogenic and vascular target drug development thorough review of approved drugs. Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls, with Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic chemotherapy agents.
Chapters within the report include:
- Executive Summary
- Methodology
- Apoptosis in Oncology
- Introduction
- Protein Kinase Inhibitors
- Antiangiogenesis and Vascular Targeting
- Appendix
- Drug Index
- Company Index
For more information visit http://www.researchandmarkets.com/reports/c66739
Source: Business Wire
Related Articles
- Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
- NCCN, Abraxis BioScience and AstraZeneca Announce Collaboration to Conduct Anti-Cancer Drug Studies
- Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
- Gain Competitive Insight into 123 Anti-Angiogenic Drugs, Under Development By 90 Investigators
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Astex Therapeutics Initiates Clinical Trial With Investigational Anti-Cancer Drug AT9283
- Humble yeast sheds light on promising anti-cancer drug
- Moffitt-USF Head Toward First Human Trials of Anti-cancer Drug that Targets Protein AKT
 |
 |
User Comments (0)
RSS Feeds